Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
CIPLA ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-23 |
ACTAVIS Dec-18 |
CIPLA/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,185 | 16,126 | - | |
Low | Rs | 852 | 10,818 | - | |
Sales per share (Unadj.) | Rs | 281.9 | 3,955.8 | - | |
Earnings per share (Unadj.) | Rs | 35.1 | -1,274.2 | - | |
Cash flow per share (Unadj.) | Rs | 49.7 | 416.9 | - | |
Dividends per share (Unadj.) | Rs | 8.50 | 0 | - | |
Avg Dividend yield | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 289.2 | 16,315.7 | - | |
Shares outstanding (eoy) | m | 807.15 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 3.4 | 106.1% | |
Avg P/E ratio | x | 29.0 | -10.6 | -274.2% | |
P/CF ratio (eoy) | x | 20.5 | 32.3 | 63.5% | |
Price / Book Value ratio | x | 3.5 | 0.8 | 426.5% | |
Dividend payout | % | 24.2 | 0 | - | |
Avg Mkt Cap | Rs m | 822,164 | 4,480,758 | 18.3% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 38,301 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 77,851.4 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,076.0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 227,531 | 1,315,689 | 17.3% | |
Other income | Rs m | 5,121 | 25,160 | 20.4% | |
Total revenues | Rs m | 232,653 | 1,340,849 | 17.4% | |
Gross profit | Rs m | 48,079 | 34,478 | 139.4% | |
Depreciation | Rs m | 11,721 | 562,428 | 2.1% | |
Interest | Rs m | 1,095 | 75,923 | 1.4% | |
Profit before tax | Rs m | 40,384 | -578,713 | -7.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,595 | 0.0% | |
Tax | Rs m | 12,029 | -7,334 | -164.0% | |
Profit after tax | Rs m | 28,355 | -423,784 | -6.7% | |
Gross profit margin | % | 21.1 | 2.6 | 806.4% | |
Effective tax rate | % | 29.8 | 1.3 | 2,350.4% | |
Net profit margin | % | 12.5 | -32.2 | -38.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 168,051 | 539,627 | 31.1% | |
Current liabilities | Rs m | 50,333 | 477,372 | 10.5% | |
Net working cap to sales | % | 51.7 | 4.7 | 1,093.4% | |
Current ratio | x | 3.3 | 1.1 | 295.4% | |
Inventory Days | Days | 73 | 20 | 374.2% | |
Debtors Days | Days | 7 | 66 | 9.8% | |
Net fixed assets | Rs m | 117,318 | 148,929 | 78.8% | |
Share capital | Rs m | 1,614 | 0 | - | |
Net worth | Rs m | 233,460 | 5,426,601 | 4.3% | |
Long term debt | Rs m | 0 | 1,910,903 | 0.0% | |
Total assets | Rs m | 290,067 | 8,483,012 | 3.4% | |
Interest coverage | x | 37.9 | -6.6 | -571.8% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.8 | 0.2 | 505.8% | |
Return on assets | % | 10.2 | -4.1 | -247.6% | |
Return on equity | % | 12.1 | -7.8 | -155.5% | |
Return on capital | % | 17.8 | -4.8 | -367.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 32,377 | 470,046 | 6.9% | |
From Investments | Rs m | -23,885 | 258,229 | -9.2% | |
From Financial Activity | Rs m | -9,583 | -806,740 | 1.2% | |
Net Cashflow | Rs m | -968 | -78,073 | 1.2% |
Compare CIPLA With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare CIPLA With: SUPRIYA LIFESCIENCE PHARMAIDS PH ABBOTT INDIA SHREE GANESH REMEDIES VINEET LABORATORIES
Indian share markets continued the momentum as the session progressed and ended the higher.